Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients.

Authors

null

Elsa Curtit

University Hospital - Medical Oncology Department, Besançon, France

Elsa Curtit , Julie Henriques , Sophie Paget-Bailly , Sylvain Ladoire , Ariane Darut-Jouve , Marc Debled , Gilles Romieu , Claire Garnier-Tixidre , Jean-Philippe Jacquin , Patrick Soulie , Christelle Jouannaud , Maria Rios , Thierry Petit , Thomas Denis Bachelot , Céline Faure-Mercier , Laetitia Gambotti , Hélène Blanché , Jean-Francois Deleuze , David Cox , Xavier Pivot

Organizations

University Hospital - Medical Oncology Department, Besançon, France, Methodology and Quality of Life Unit, Department of Oncology University Hospital, Besançon, France, Methodological and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital, Besançon, France, Dpt of Medical Oncology, Centre Georges François Leclerc, Dijon, France, Centre de Radiothérapie du Parc, Dijon, France, Institut Bergonié, Bordeaux, France, CRLC Val d'Aurelle, Montpellier, France, GINECO-Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France, GINECO-Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-En-Jarez, France, Institut de Cancérologie de l'Ouest, Angers, France, Institut Jean Godinot, Reims, France, Centre Alexis Vautrin, Nancy, France, Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France, GINECO-Centre Léon Bérard, Lyon, France, Institut National du Cancer INCA, Boulogne-Billancourt, France, French National Cancer Institute, Boulogne-Billancourt, France, Human Polymorphism Study Center, Paris, France, CNRGH, Evry, France, Sophia Genetics, Lyon, France, Administrateur de l’Institut Régional du Cancer, Strasbourg Cedex, France

Research Funding

Other Government Agency

Background: Triple-negative breast cancers (TNBC) are a heterogeneous group of tumors with poor outcome. In this study, the association between germline genetic variants and invasive disease-free survival (iDFS) was analyzed in TNBC patients. Methods: A genome wide-association study (GWAS) aimed to identify variants (single nucleotide polymorphisms – SNPs) associated with prognosis in 1121 patients with TNBC in the SIGNAL prospective cohort. Associations between gene variants and iDFS were assessed in univariate Cox regression models. Variants were combined in a score to identify risk categories. A prognostic model based on breast cancer stage and genetic variants was estimated using a multivariate Cox regression. Interaction between stage and genetic score was tested. Discrimination of the model was assessed by the Harrell’s C statistic and internal validity by bootstrap method. Results: The characteristics of the 1121 patients were representative of a population with early TNBC. Four SNPs on chromosomes 9 and 2 were found significantly associated to iDFS in univariate Cox models. Homozygous status for the most frequent allele was associated with poorer iDFS for two SNPs and this status was present in 50% and 57% of the population. For the two other SNPs, the most frequent allele was associated with more favorable iDFS. Three prognostic categories were derived from the genetic score. The following table presents the results from the multivariate Cox model including genetic score and disease stage. Clinical trial information: RECF1098.Conclusions: In a prospective cohort of 1121 patients with early TNBC, 4 genetic variants (SNPs) were associated with iDFS. A score involving SNPs provided similar prognostic indications as breast cancer stages. A search assessing the function and the role of the involved genes is ongoing.

n (events)HR95%CIBootstrap 95% CIpvalue
1017* (204)
stageI347 (40)1< 0,0001
II484 (90)1,641,13-2,381,00-2,83
III177 (74)4,863,31-7,153,03-8,7
scorelow652 (93)1< 0,0001
medium311 (90)2,291,71-3,061,52-3,37
high45 (21)4,582,85-7,372,15-9,37

* missing data: 104 / C-Harrell at 0.71 (95% CI 0.67-0.75) No significant interaction was found between stage and genetic score (p = 0.5184).

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Cancer Prevention, Hereditary Genetics, and Epidemiology

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Cancer Genetics

Clinical Trial Registration Number

RECF1098

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1529)

DOI

10.1200/JCO.2019.37.15_suppl.1529

Abstract #

1529

Poster Bd #

23

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).

First Author: Yan Yang

First Author: Holly Jane Pederson